China Universal Asset Management Co. Ltd. Boosts Stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

China Universal Asset Management Co. Ltd. lifted its holdings in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 10.8% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 8,106 shares of the company’s stock after acquiring an additional 789 shares during the quarter. China Universal Asset Management Co. Ltd.’s holdings in Tarsus Pharmaceuticals were worth $449,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also bought and sold shares of the company. R Squared Ltd bought a new stake in shares of Tarsus Pharmaceuticals in the fourth quarter worth approximately $53,000. Franklin Resources Inc. raised its stake in Tarsus Pharmaceuticals by 9.3% during the 3rd quarter. Franklin Resources Inc. now owns 12,164 shares of the company’s stock valued at $444,000 after buying an additional 1,033 shares during the last quarter. The Manufacturers Life Insurance Company lifted its holdings in shares of Tarsus Pharmaceuticals by 10.3% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 33,282 shares of the company’s stock valued at $905,000 after buying an additional 3,112 shares during the period. SG Americas Securities LLC boosted its stake in shares of Tarsus Pharmaceuticals by 87.5% in the 3rd quarter. SG Americas Securities LLC now owns 7,242 shares of the company’s stock worth $238,000 after buying an additional 3,379 shares during the last quarter. Finally, FMR LLC grew its holdings in shares of Tarsus Pharmaceuticals by 236.6% in the third quarter. FMR LLC now owns 5,032 shares of the company’s stock worth $166,000 after acquiring an additional 3,537 shares during the period. Hedge funds and other institutional investors own 90.01% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have issued reports on TARS shares. Oppenheimer raised their target price on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 22nd. The Goldman Sachs Group raised their price objective on shares of Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the stock a “neutral” rating in a report on Friday, November 15th. Finally, Barclays upped their target price on shares of Tarsus Pharmaceuticals from $60.00 to $62.00 and gave the company an “overweight” rating in a report on Monday, January 27th. One investment analyst has rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Tarsus Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $56.00.

Tarsus Pharmaceuticals Trading Up 3.9 %

Tarsus Pharmaceuticals stock opened at $53.76 on Monday. Tarsus Pharmaceuticals, Inc. has a 12-month low of $20.08 and a 12-month high of $57.14. The firm has a market capitalization of $2.06 billion, a price-to-earnings ratio of -14.11 and a beta of 1.02. The firm has a 50 day moving average of $51.61 and a 200 day moving average of $39.93. The company has a current ratio of 5.42, a quick ratio of 5.38 and a debt-to-equity ratio of 0.30.

Tarsus Pharmaceuticals Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.